BTG (LON:BTG)‘s stock had its “hold” rating restated by stock analysts at Deutsche Bank in a research note issued on Tuesday. They currently have a GBX 645 ($8.32) price objective on the stock. Deutsche Bank’s price objective indicates a potential upside of 17.92% from the company’s current price.
Several other analysts also recently issued reports on BTG. Shore Capital restated a “buy” rating on shares of BTG in a research note on Friday, June 15th. Numis Securities restated a “buy” rating on shares of BTG in a research note on Friday, June 15th. Jefferies Financial Group boosted their price target on BTG from GBX 775 ($10.00) to GBX 900 ($11.61) and gave the company a “buy” rating in a research note on Tuesday, May 15th. Finally, Peel Hunt restated a “hold” rating on shares of BTG in a research note on Tuesday, July 3rd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of GBX 697.50 ($9.00).
BTG stock opened at GBX 547 ($7.06) on Tuesday. BTG has a 1-year low of GBX 559.82 ($7.22) and a 1-year high of GBX 784 ($10.11).
In other news, insider Duncan Kennedy sold 2,652 shares of the company’s stock in a transaction on Friday, June 8th. The stock was sold at an average price of GBX 556 ($7.17), for a total transaction of £14,745.12 ($19,021.05). Also, insider Dame Pamela Louise Makin sold 73,410 shares of the company’s stock in a transaction on Tuesday, July 17th. The shares were sold at an average price of GBX 488 ($6.30), for a total value of £358,240.80 ($462,126.93).
BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. It operates through three segments: Interventional Medicine, Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications.
Featured Story: Should you buy a closed-end mutual fund?
Receive News & Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related companies with MarketBeat.com's FREE daily email newsletter.